Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma

¹¹C-choline positron emission tomography/computed tomography (PET/CT) has been used in patients with some types of solid cancers, but few data are available in patients undergoing hepatectomy for hepatocellular carcinoma (HCC). The aim of this study was to analyze the prognostic value of metabolic imaging data by using ¹¹C-choline PET/CT in patients with HCC before hepatectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Our prospectively maintained liver unit database was queried for patients with HCC preoperatively staged with ¹¹C-choline PET/CT. This metabolic imaging modality was performed in addition to standard abdominal CT or magnetic resonance imaging. Several PET/CT parameters were recorded and analyzed. Univariate and multivariate analyses were performed to identify whether those PET/CT parameters could be predictors of overall survival (OS) and disease-free survival (DFS) of HCC patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Any patient with HCC candidate to surgical resection preoperatively staged with ¹¹C-choline PET/CT

Exclusion criteria

R2 resection;
Intraoperative use of RFA/MWI
Postoperative death (90-days)

Treatment and study plan

Hepatectomy

Procedure

Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma

Other names: Hepatic resection; liver resection.

Primary outcomes

Identification of PET/CT parameters that can be predictors of survival

Time frame: From date of surgery until the date of first documented progression or date of death from any cause, whichever came first assessed up to 72 months

Identification of specific PET/CT parameters that can be used as independent predictors of overall and/or disease-free survival

Sponsors and collaborators

Lead sponsor

Humanitas Clinical and Research Center

Other

Registry information

Official study title

What is the Prognostic Value of ¹¹C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma?

Important dates

Study start: 2010
Primary completion: 2015
Study completion: 2016
First posted: Feb 13, 2018
Registry last updated: Feb 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed